Conclusions: Our 3-y FU data reinforce the concept that TAVI should be avoided when the native aortic valve is degenerated (n ≥ 8.5 cm). In this context the larger CoreValve available (31 mm) cannot be use as oversizing prosthesis. To the contrary when an oversizing valve prosthesis can be used acceptable results are achieved. In this setting of pts TAVI showed no death, and good clinical outcomes that were sustained at 3-y FU.

TCT-756
Incidence, Predictors, and Prognostic Impact of Late Bleeding (≥30 days) Complications after Transcatheter Aortic Valve Replacement (TAVR)
Philippe Generex1, David Cohen1, Michael Mack1, Joseph Rodes-Cabau1, Mayank Yadav1, Ke Xu1, Webb John1, Martin Leon1
1Columbia University Medical Center, New York, 2Saint Luke’s Mid America Heart Institute, Kansas City, United States, 3Baylor Healthcare System, Plano, United States, 4Quebec Heart and Lung Institute, Quebec, Canada, 5Cardiovascular Research Foundation, New York, NY, 6Cardiovascular Research Foundation, New York, NY, 7St Pauls Hospital, Vancouver, British Columbia, 8Cardiovascular Research Foundation, New York, United States

Background: The incidence and prognostic impact of late bleeding complications (LBC) after TAVR are unknown. We sought to identify the incidence, predictors, and prognostic impact of LBC (≥30 days) after TAVR.

Methods: Clinical and echocardiographic outcomes of patients who underwent TAVR within the randomized cohorts and continued access registries in the PARTNER trial were analyzed after stratifying by the occurrence of LBC. Predictors of LBC and its association with 30-day to 1-year mortality were assessed.

Results: Among 2,401 patients who underwent TAVR and survived to 30 days, LBC occurred in 142 (5.9%) at median time of 132 [71, 230] days after the index procedure. Among 2,401 patients who underwent TAVR and survived to 30 days, LBC and its association with 30-day to 1-year mortality were assessed.

Conclusions: LBC after TAVR were frequent and associated with increased mortality. A better-individualized and risk-adjusted antithrombotic therapy after TAVR is urgently needed in this high-risk population.

TCT-757
Long-Term Results Following Transcatheter Aortic Valve Implantation
Pablo Codner1, Abid Assali2, Hana Vaknin-Axel2, Yaron Shapira2, Gabriel Greenberg3, Katia Orvin4, Leor Perl4, Marina Kupershmidt3, Pablo Codner1, Abid Assali2, Hana Vaknin-Axel2, Yaron Shapira2, Gabriel Greenberg3, Katia Orvin4, Leor Perl4, Marina Kupershmidt3
1Columbia University Medical Center, New York, 2Saint Luke’s Mid America Heart Institute, Kansas City, United States, 3Baylor Healthcare System, Plano, United States, 4Quebec Heart and Lung Institute, Quebec, Canada, 5Cardiovascular Research Foundation, New York, NY, 6Cardiovascular Research Foundation, New York, NY, 7St Pauls Hospital, Vancouver, British Columbia, 8Cardiovascular Research Foundation, New York, United States

Background: Long-term clinical outcomes of patients treated with transcatheter aortic valve implantation (TAVI) continue to be urgently needed.

Methods: Clinical and echocardiographic outcomes of patients who underwent TAVI at our center from January 2010 to December 2012 were analyzed. Clinical and echocardiographic outcomes of patients treated by TAVI were analyzed until 3 years, and outcome was analyzed in 275 patients who were followed up to 3 years (mean 702 days).

Results: The incidence of major complications was 25% (odds ratio: 2.3, 95% confidence interval: 1.5–3.5). The incidence of paravalvular leak was 7% (odds ratio: 1.7, 95% confidence interval: 1.1–2.7). The incidence of stroke was 7% (odds ratio: 2.2, 95% confidence interval: 1.2–4.0). The incidence of瓣膜性心力衰竭 was 5% (odds ratio: 1.7, 95% confidence interval: 1.1–2.7). The incidence of pacemaker implantation was 12% (odds ratio: 2, 95% confidence interval: 1–4).

Conclusions: The current report signifies that catheter-based treatment of mostly elderly patients with severe aortic stenosis is feasible, safe and associated with satisfactory long-term outcomes.

TCT-758
Hemodynamic Changes After Transcatheter Aortic Valve Implantation (TAVI) Significantly Influence Renal Function Thereby Impacting On Mortality
Lisa Voigtländer1, Jury Schewel1, Julia Martin2, Dimitry Schewel1, Christian Freker3, Peter Wohlmuth4, Thielen Thomas4, Karl-Heinz Kuck1, Ulrich Schäfer1
1Department of Cardiology, Asklepios Klinik St.Georg, Hamburg, Germany, 2Department of Cardiology, Asklepios Klinik St Georg; Hamburg, Germany, 3Department of Cardiology, Asklepios Klinik St.Georg, Hamburg, Germany, 4Department of Cardiology, Asklepios Klinik St.Georg, Hamburg, Germany, 5Department of General and Interventional Cardiology, University Heart Centre Hamburg, Hamburg, Germany

Background: Acute kidney injury (AKI) is a serious complication after transcatheter aortic valve implantation (TAVI) and patients with preexisting renal impairment seem to be especially prone to AKI. Very few data exist about the impact of invasive hemodynamics on the occurrence of AKI after TAVI. The objectives of the study were (i) to determine the incidence and predictive factors for AKI with emphasis on invasive hemodynamics, and (ii) to examine short- and long-term outcome of these patients.

Methods: A total of 540 patients (mean age: 80.2±7.1, logES: 24.5±17.9%) undergoing TAVI were included in the study. Patients were divided into three groups according to their glomerular filtration rate (GFR) before TAVI (A: normal renal function i.e. GFR ≥ 60ml/min; B: impaired renal function i.e. GFR 30-59 ml/min; C: severe impaired renal function i.e. GFR < 30 ml/min). Renal function and survival were recorded over 12 months.

Results: Overall 30-day mortality was 10.2% and 12-month mortality was 21.5%.

Subgroup analysis showed significant differences between the groups with regard to 30-day mortality (A: 5.4%; B: 9.0%; C: 25.0%) and 12-month mortality (A: 15.0%; B: 32.0%; C: 49%). AKI occurred in 30 patients (5.6%), of which the majority were patients of group B (16 patients). 30-day mortality of patients with AKI was 53.3% (16 patients) and 12-month mortality was 73.3% (22 patients). Systemic arterial pressures were significantly higher before and after TAVI in patients without AKI compared to patients with AKI whereas preprocedural and postprocedural pulmonary and right atrial pressures did not differ between both groups. Predictive factors for
Morley Herbert4, Ethan Ungchusri1, Rebeca J. Kim1, Christina Worley1, United States

Preprocedural renal dysfunction is a prominent impact on mortality after TAVI. In addition, the occurrence of AKI after TAVI carries an even worse prognosis. In this regard, the maintenance of a sufficient blood pressure and an increase of cardiac output after TAVI seem to be protective against renal impairment.

Conclusions: Preprocedural renal dysfunction has a prominent impact on mortality after TAVI. In addition, the occurrence of AKI after TAVI carries an even worse prognosis. In this regard, the maintenance of a sufficient blood pressure and an increase of cardiac output after TAVI seem to be protective against renal impairment.

TCT-759
Early Detection of Acute Kidney Injury Post Transcatheter Aortic Valve Replacement By a Novel Renal Biomarker
Elizabeth M. Holper1, Robert A. Farkas1, Harold M. Szerlip1, Molly Szerlip1, Morley Herbert1, Ethan Ungchusri1, Rebecca J. Kim1, Christina Worley1, Melissa Johnson1, Michael Mack1
1Cardiopulmonary Research Science and Technology Institute, Dallas, TX, 2Medical City Hospital, Dallas, TX, 3Heart Hospital Baylor Plano, Plano, TX, 4Medical City Dallas Hospital, Dallas, TX, 5Baylor Healthcare System, Plano, United States

Background: Neutrophil gelatinase-associated lipocalin (NGAL) is a novel biomarker associated with acute kidney injury (AKI) after cardiac procedures. NGAL allows earlier detection of AKI than serum creatinine (SCr) level but has not been evaluated in a post transcatheher aortic valve replacement (TAVR) population.

Methods: From 6/2012-5/2013, we enrolled 66 patients undergoing TAVR in this single-center pilot study. Urinary NGAL was measured at baseline, 2, 4, and 12 hours post op. Demographic, procedural features, and SCr until discharge were measured. The trend of NGAL post TAVR and the association of increased NGAL with AKI as per VARC-2 criteria was assessed.

Results: Twenty-two patients (33.3%) developed AKI postoperatively (Stage 1, 63.6%; Stage 2, 22.7%; Stage 3, 13.6%). There was no significant difference in baseline SCr, eGFR, or contrast dye volume between patients who developed AKI and those who did not but AKI patients had a significantly smaller aortic valve area. There was a significantly higher level of NGAL in patients with AKI versus those without AKI seen at 2, 4, and 12 hours post procedure (Figure), with the peak at 2 hours. After adjusting for gender, age, diabetes, TAVR type, and BMI, NGAL was significantly predictive of AKI at baseline (OR = 1.019 (95% CI 1.001 – 1.037, p = 0.034) and at each post op measurement.

Conclusions: NGAL was significantly elevated in patients who develop AKI both pre TAVR and post TAVR as early as 2 hours post procedure in this pilot study. This biomarker may assist in better determining patients at risk for and earlier detection and management of this frequent complication.

TCT-760
Treatment of Acquired von Willebrand Syndrome in Aortic Stenosis with Transcatheter Aortic Valve Replacement (TAVR)
Tobias Spangenberg1, Ulrich Baade2, Thielsen Thomas3, Christian Frekker1, Karl-Heinz Kuck1, Ulrich Schäfer2
1Department of Cardiology, Asklepios Klinik St.Georg, Hamburg, Germany, 2Hamburg, Hamburg, 3Medilys Laborgesellschaft, Hamburg, Hamburg, 4Department of Cardiology, Asklepios Klinik St. Georg, Hamburg, Germany, Hamburg, Germany

Background: Association between the acquired von Willebrand syndrome (aVWS) and valvular aortic stenosis (AVS) has been demonstrated in the past. While the extent of von Willebrand factor (vWF) deficiency is related to the severity of AVS, surgical valve replacement (SAVR) can lead to factor recovery. Prevalence and course of the aVWS in patients treated with TAVR though has not yet been described comprehensively. Thus, we investigated the prevalence of the aVWS in patients undergoing TAVR and the impact on the underlying factor variances.

Methods: 104 consecutive patients (age: 81.0 ± 13.0 years; logEuroScore 22.9±18.5%) underwent TAVR at our institution. Comprehensive hemostasologic testing was performed prior to and up to one week after TAVR. Transvalvular hemodynamics and right heart catheterisation as well as bleeding episodes were recorded and analyzed with descriptive statistics.

Results: Baseline prevalence of an aVWS was 41% with an average densitometric high-molecular-weight multimer (HMW-MM) count of 16.6±3.5%. Pressure gradients correlated significantly with the extent of high-molecular-weight multimer (HMW-MM) deficiency (r = 0.63 [P < 0.0001]). While in the past it has been shown to be vice-versa for SAVR, the necessity of blood transusions was higher in our control group. Following valve implantation, HMW-MM increased proportional to the drop in mean pressure gradient and normalized within a week in 97% of the patients with prior aVWS.

Conclusions: We describe a significant prevalence of aVWS in patients undergoing TAVR. Since severe factor deficiency can lead to significant bleeding during SAVR, TAVR should be taken into consideration as a first line treatment for patients with AVS and concomitant aVWS.

TCT-761
Balloon-Expandable Transcatheter Aortic Valves Can Be Effectively And Safely Implanted Transfemorally Without Balloon Valvuloplasty
Saneel K. Aggarwal1, Nicola Delahunty2, Sarah Early1, Emmanuel Ako2, Mun-Hong Cheang1, Markus Reinhalter1, Azad N. Taminii2, Cynthia Cheng1, John Yap1, Muhammad Oskor2
1The Heart Hospital, University College London Hospitals, London, United Kingdom

Background: Balloon aortic valvuloplasty (BAV) has traditionally been part of the transcatheter aortic valve implantation (TAVI) procedure using balloon expandable valves. However, the benefit of this is unknown. We aimed to evaluate procedural success and safety in patients who underwent TAVI with and without BAV.

Methods: We retrospectively evaluated all TAVIs performed for predominant aortic stenosis using the balloon-expandable Edwards Sapien XT and Sapien 3 devices from March 2012 to April 2014. BAV was routinely performed only until May 2013. We assessed Valve Academic Research Consortium (VARC)-2 defined device success and safety; differences in procedure and fluoroscopy times and differences in embolic load based on transcranial Doppler (TCD). Categorical variables were analyzed using the Fisher exact test and continuous variables by the unpaired T-test on SPSS v21.

Results: 61 patients underwent BAV (Group 1) and 52 patients had no BAV (Group 2). There was no difference (p>0.05) in the rate of device success, specifically successful valve deployment (98.3% in Group 1 and 96.1% in Group 2), rate of post-deployment balloon dilatation (0.4% in Group 1 and 4.0% in Group 2) or incidence of moderate or severe aortic regurgitation (4.9% in Group 1 and 5.8% in Group 2). There were no differences in procedure safety (50.8% VARC-2 defined major and minor complications in Group 1 and 34.6% in Group 2, p=0.15). In one case there was difficulty in crossing the valve without BAV, partial inflation of the distal balloon tip within the TAVI valve enabled crossing of the native aortic valve without subsequent deployment problems. There was a reduction in total fluoroscopic time in Group 2 vs Group 1 (13.2 vs 17.3 mins, p=0.006), but no significant difference in total procedure time (112 vs 119 mins, p=0.21). There were no differences between the 2 groups in terms of number of solid, gaseous or total emboli on TCD (all p>0.05).

Conclusions: Balloon-expandable TAVI valves can be implanted transfemorally without BAV, without a reduction in VARC-2 defined success or safety. Without performing a BAV there is a significant reduction in the fluoroscopic time. There is no difference in the rate of embolization on TCD.

TCT-762
Transcatheter Aortic Valve Implantation: A Single Center Comparison between Medtronic CoreValve and Edwards SAPIEN Bioprostheses
Eygal Ben-Av2, Yigal Abramowicz2, Aron Steinberg2, Eran Leshem-Rubinov2, Ofer Havakuk1, Maayan Konigstein2, Yaron Arbel1, Amir Halkin1, Gad Keren1, Shmuel Banai1, Ariel Finkelstein1
1Tel Aviv Medical Center, Tel Aviv, Israel

Background: Transcatheter aortic valve implantation (TAVI) is the new standard of care for inoperable patients with severe aortic stenosis and an alternative to surgical procedures. However, the benefit of this is unknown. We aimed to evaluate procedural success and safety in patients who underwent TAVI with and without BAV.